GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (LTS:0K95) » Definitions » Valuation Rank

Northwest Biotherapeutics (LTS:0K95) Valuation Rank


View and export this data going back to 2018. Start your Free Trial

What is Northwest Biotherapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Northwest Biotherapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Northwest Biotherapeutics (LTS:0K95) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (LTS:0K95) » Definitions » Valuation Rank
Comparable Companies
CABA YMAB ALLO ALT HRTX OABI TRDA LXEO CDMO ADPT OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
NWBO:USA NBYB:Germany
Address
4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Website
https://www.nwbio.com
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.